Show simple item record

dc.contributor.authorAyala-Suárez, Rubén 
dc.contributor.authorGracia-Ruíz de Alda, María
dc.contributor.authorDiez-Fuertes, Francisco 
dc.contributor.authorCalonge-Errejon, Maria Esther 
dc.contributor.authorTorre Tarazona, Humberto Erick de la 
dc.contributor.authorCapa, Laura 
dc.contributor.authorAlcamí, José 
dc.date.accessioned2020-09-14T07:38:42Z
dc.date.available2020-09-14T07:38:42Z
dc.date.issued2020-07-31
dc.identifier.citationJ Clin Med. 2020 Jul 31;9(8):2452.es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11008
dc.descriptionFactor de impacto: 4,242 Q1
dc.description.abstractLong-term non-progressors (LTNP) and elite controllers (EC) represent spontaneous natural models of efficient HIV-1 response in the absence of treatment. The main purposes of this work are to describe the miRNome of HIV-1 infected patients with different extreme phenotypes and identify potentially altered pathways regulated by differentially expressed (DE) miRNAs. The miRNomes from peripheral blood mononuclear cells (PBMCs) of dual phenotype EC-LTNP or LTNP with detectable viremia and HIV-infected patients with typical progression before and after treatment, were obtained through miRNA-Seq and compared among them. The administration of treatment produces 18 DE miRNAs in typical progressors. LTNP condition shows 14 DE miRNA when compared to typical progressors, allowing LTNP phenotype differentiation. A set of four miRNAs: miR-144-3p, miR-18a-5p, miR-451a, and miR-324 is strongly downregulated in LTNP and related to protein regulation as AKT, mTOR, ERK or IKK, involved in immune response pathways. Deregulation of 28 miRNA is observed between EC-LTNP and viremic-LTNP, including previously described anti-HIV miRNAs: miR-29a, associated with LTNP phenotype, and miR-155, targeting different pre-integration complexes such as ADAM10 and TNPO3. A holistic perspective of the changes observed in the miRNome of patients with different phenotypes of HIV-control and non-progression is provided.es_ES
dc.description.sponsorshipThis study has been conducted within the Spanish AIDS Research Network (RIS), funded by Instituto de Salud Carlos III (Plan Estatal de I+D+I 2013-2016) and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (RD12/0017/0015 and RD16CIII/0002/0001 projects), and the European Union’s Horizon 2020 Research and Innovation Programme under grant number 681137. The HIV BioBank, integrated in the Spanish AIDS Research Network, is partially funded by the RD16/0025/0019 project as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación and el Fondo Europeo de Desarrollo Regional (FEDER). R.A.-S. was supported by the Ministry of Innovation, Science and Universities predoctoral funding (FPU18/05527) and H.E.T.-T. by the ISCIII-PFIS predoctoral program (FI14CIII/00014).es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHIV-1 infectiones_ES
dc.subject.meshbiomarker discoveryes_ES
dc.subject.meshdifferential expressiones_ES
dc.subject.meshelite controllerses_ES
dc.subject.meshlong-term non-progressorses_ES
dc.subject.meshmiRNA-Seqes_ES
dc.subject.meshmiRNomees_ES
dc.titleInsight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infectiones_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32751854es_ES
dc.format.volume9es_ES
dc.format.number8es_ES
dc.format.page2452es_ES
dc.identifier.doi10.3390/jcm9082452es_ES
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.description.peerreviewedes_ES
dc.identifier.e-issn2077-0383es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm9082452es_ES
dc.identifier.journalJournal of clinical medicinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/681137es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16/0025/0019es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0017/0015es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FPU18/05527es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FI14CIII/00014es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional